We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | 장 마감 후 (AMC) | — | — | — | $420K | — | 예정 |
Consensus PT $17.5 · 2 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 02. 24. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 01. 06. | Jones Trading | — | 커버리지 개시 | — → Buy | — | Jones Trading: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Stored first · Google News · Yahoo Finance (English)
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 MSN
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Low Vol ETF - thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Low Vol ETF thelegaladvocate.com
ARMP Stock Chart | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
ARMP Stock Chart | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) ChartMill
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Steep EPS Miss as Clinical-Stage Biotech Continues Heavy R&D Spending - Earnings Per Share - thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Steep EPS Miss as Clinical-Stage Biotech Continues Heavy R&D Spending - Earnings Per Share thelegaladvocate.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline Progress - thelegaladvocate.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline Progress thelegaladvocate.com
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 Moomoo